Search

Your search keyword '"Touw, Daan J"' showing total 1,006 results
Start Over Author "Touw, Daan J"
1,006 results on '"Touw, Daan J"'

1. Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology – an analysis of the closed cohorts of a multicentre prospective study

Author

van der Kleij, Maud B. A., Guchelaar, Niels A. D., Meertens, Marinda, Westerdijk, Kim, Giraud, Eline L., Bleckman, Roos F., Groenland, Stefanie L., van Eerden, Ruben A. G., Imholz, Alex L. T., Vulink, Annelie J. E., Otten, Hans-Martin, Fiebrich-Westra, Helle-Brit, Lubberman, Floor J. E., Desar, Ingrid M. E., Moes, Dirk-Jan A. R., Touw, Daan J., Koolen, Stijn L. W., Gelderblom, Hans, Reyners, An K. L., van Erp, Nielka P., Mathijssen, Ron H. J., Huitema, Alwin D. R., and Steeghs, Neeltje

Published
2024
Full Text
View/download PDF

3. Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort

Author

Meertens, Marinda, Giraud, Eline L., van der Kleij, Maud B. A., Westerdijk, Kim, Guchelaar, Niels A. D., Bleckman, Roos F., Rieborn, Amy, Imholz, Alex L. T, Otten, Hans-Martin, Vulink, Annelie, Los, Maartje, Hamberg, Paul, van der Graaf, Winette T. A., Gelderblom, Hans, Moes, Dirk Jan A. R., Broekman, K. Esther, Touw, Daan J., Koolen, Stijn L. W., Mathijssen, Ron H. J., Huitema, Alwin D. R., van Erp, Nielka P., Desar, Ingrid M. E., and Steeghs, Neeltje

Published
2024
Full Text
View/download PDF

8. Iron Deficiency and Nephrotoxic Heavy Metals: A Dangerous Interplay?

Author

Rawee, Pien, Kremer, Daan, Nolte, Ilja M, Leuvenink, Henri GD, Touw, Daan J, De Borst, Martin H, Bakker, Stephan JL, Hanudel, Mark R, and Eisenga, Michele F

Subjects
Biochemistry and Cell Biology, Biological Sciences, Medicinal and Biomolecular Chemistry, Chemical Sciences, Microbiology, Kidney Disease, Nutrition, 2.1 Biological and endogenous factors, Aetiology, Renal and urogenital, Humans, Metals, Heavy, Iron, Heavy Metal Poisoning, Iron Deficiencies, Renal Insufficiency, Chronic, iron deficiency, heavy metals, nephrotoxic, chronic kidney disease, metal transporters, Other Chemical Sciences, Genetics, Other Biological Sciences, Chemical Physics, Biochemistry and cell biology, Medicinal and biomolecular chemistry
Abstract

Heavy metals are common in our environment, and all individuals are exposed to them to some extent. These toxic metals have several harmful effects on the body, including the kidney, which is a very sensitive organ. Indeed, heavy metal exposure has been linked to an increased risk of chronic kidney disease (CKD) and its progression, which may be explained by the well-established nephrotoxic effects of these metals. In this hypothesis and narrative literature review, we will shed light on the potential role that another highly common problem in patients with CKD, iron deficiency, may play in the damaging effects of heavy metal exposure in this patient group. Iron deficiency has previously been linked with an increased uptake of heavy metals in the intestine due to the upregulation of iron receptors that also take up other metals. Furthermore, recent research suggests a role of iron deficiency in the retention of heavy metals in the kidney. Therefore, we hypothesize that iron deficiency plays a crucial role in the damaging effects of heavy metal exposure in patients with CKD and that iron supplementation might be a strategy to combat these detrimental processes.

Published
2023

10. Iron deficiency, anemia, and patient-reported outcomes in kidney transplant recipients

Author

Ranchor, Adelta V., Gomes Neto, Antonio W., Diepstra, Arjan, Hepkema, Bouke G., Tji Gan, C., Doorenbos, Caecilia S.E., te Velde-Keyzer, Charlotte A., van Leer-Buter, Coretta, Touw, Daan J., Hak, Eelko, Verschuuren, Erik A.M., Bodewes, Frank A.J.A., Klont, Frank, Dijkstra, Gerard, Nieuwenhuis-Moeke, Gertrude J., Blokzijl, Hans, Leuvenink, Henri G.D., Niesters, Hubert G.M., Cas Swarte, J., Sanders, Jan Stephan F., Damman, Kevin, Joost van Pelt, L., van Londen, Marco, de Boer, Marieke T., Siebelink, Marion J., van den Heuvel, Marius C., Vos, Michel J., Erasmus, Michiel E., Douwes, Rianne M., Slart, Riemer J.H.J.A., Weersma, Rinse K., Pol, Robert A., Porte, Robert J., de Meijer, Vincent E., Lexmond, Willem S., Kremer, Daan, Knobbe, Tim J., Vinke, Joanna Sophia J., Groothof, Dion, Post, Adrian, Annema, Coby, Abrahams, Alferso C., van Jaarsveld, Brigit C., de Borst, Martin H., Berger, Stefan P., Bakker, Stephan J.L., and Eisenga, Michele F.

Published
2024
Full Text
View/download PDF

18. Central Body Fat Distribution and Kidney Function after Living Kidney Donation

Author

Westenberg, Lisa B., Pol, Robert A., van der Weijden, Jessica, de Borst, Martin H., Bakker, Stephan J.L., van Londen, Marco, Annema, Coby, Berger, Stefan P., Blokzijl, Hans, Bodewes, Frank A.J.A., de Boer, Marieke T., Damman, Kevin, de Borst, Martin H., Diepstra, Arjan, Dijkstra, Gerard, Douwes, Rianne M., Doorenbos, Caecilia S.E., Eisenga, Michele F., Erasmus, Michiel E., Gan, C. Tji, Gomes Neto, Antonio W., Hak, Eelko, Hepkema, Bouke G., van den Heuvel, Marius C., Klont, Frank, Knobbe, Tim J., Kremer, Daan, van Leer-Buter, Coretta, Leuvenink, Henri G.D., van Londen, Marco, Lexmond, Willem S., de Meijer, Vincent E., Niesters, Hubert G.M., Nieuwenhuis-Moeke, Gertrude J., Joost van Pelt, L., Pol, Robert A., Porte, Robert J., Ranchor, Adelta V., Sanders, Jan Stephan F., Siebelink, Marion J., Slart, Riemer J.H.J.A., Swarte, J. Cas, Touw, Daan J., te Velde-Keyzer, Charlotte A., Verschuuren, Erik A.M., Vos, Michel J., Weersma, Rinse K., and Bakker, Stephan J.L.

Published
2024
Full Text
View/download PDF

22. Proton Pump Inhibitor Use, Fatigue, and Health-Related Quality of Life in Kidney Transplant Recipients: Results From the TransplantLines Biobank and Cohort Study

Author

Blokzijl, Hans, Bodewes, Frank A.J.A., de Boer, Marieke T., Damman, Kevin, de Borst, Martin H., Diepstra, Arjan, Dijkstra, Gerard, Doorenbos, Caecilia S.E., Erasmus, Michiel E., Gan, C. Tji, Hak, Eelko, Hepkema, Bouke G., Leuvenink, Henri G.D., Lexmond, Willem S., de Meijer, Vincent E., Niesters, Hubert G.M., van Pelt, L. Joost, Pol, Robert A., Porte, Robert J., Ranchor, Adelta V., Sanders, Jan Stephan F., Siebelink, Marion J., Slart, Riemer J.H.J.A., Touw, Daan J., van den Heuvel, Marius C., van Leer-Buter, Coretta, van Londen, Marco, Verschuuren, Erik A.M., Vos, Michel J., Weersma, Rinse K., Knobbe, Tim J., Kremer, Daan, Douwes, Rianne M., Eisenga, Michele F., Gomes-Neto, António W., Annema, Coby, Swarte, J. Casper, Klont, Frank, Navis, Gerjan, Berger, Stefan P., and Bakker, Stephan J.L.

Published
2023
Full Text
View/download PDF

23. Correction: Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between UGT1A1 and irinotecan

Author

Hulshof, Emma C., Deenen, Maarten J., Nijenhuis, Marga, Soree, Bianca, de Boer-Veger, Nienke J., Buunk, Anne-Marie, Houwink, Elisa J. F., Risselada, Arne, Rongen, Gerard A. P. J. M., van Schaik, Ron H. N., Touw, Daan J., van der Weide, Jan, van Westrhenen, Roos, Deneer, Vera H. M., Guchelaar, Henk-Jan, and Swen, Jesse J.

Published
2023
Full Text
View/download PDF

35. Infliximab in paediatric inflammatory bowel disease: External evaluation of population pharmacokinetic models.

Author

Heikal, Omnia Salah, van Rheenen, Patrick F., Touw, Daan J., Kosterink, Jos G. W., Maurer, Marina, Koomen, Jeroen V., Chelle, Pierre, and Mian, Paola

Subjects
INFLAMMATORY bowel diseases, PHARMACOKINETICS, INFLIXIMAB, NECROSIS, PEDIATRICS
Abstract

Aims: Use of infliximab (IFX) has improved outcomes in children with inflammatory bowel disease (IBD). However, a proportion of patients does not respond to IFX or loses response over time. Population pharmacokinetic (PopPK) modelling is a promising approach for IFX dose optimization, but with the increasing number of PopPK models in literature, model evaluation is essential. The aims of this study are: (i) to validate the predictive performance of existing IFX PopPK models using a cohort of children with IBD; and (ii) to perform a Bayesian estimation of the most suitable model to predict the next IFX concentrations. Methods: PubMed was searched for IFX PopPK models in children. Selected models were rebuilt and analysed using R. Model performance was assessed through goodness‐of‐fit‐plots, residuals against time, prediction error and prediction‐corrected visual predictive checks. The validation cohort consisted of 73 children with IBD who were treated with IFX in our centre between 2017 and 2023 (340 IFX measurements). Results: We identified 9 PopPK models. Model bias for individual predicted values ranged from −9.29% to 8.01% compared to bias for population predicted values. The model by Vande Casteele et al. demonstrated superior performance (individual predicted bias 2.13, population predicted bias −6.11); upon Bayesian estimation, it predicted induction trough levels with median error of 12.95% but had a median error of −69% predicting maintenance concentrations. Conclusion: The model by Vande Casteele et al. displayed superior performance in initial evaluations but had a high error in estimating next IFX levels and can only be used in practice to predict induction levels. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-Aand HLA-Bwith anti-epileptic drugs

Author

Manson, Lisanne E. N., Nijenhuis, Marga, Soree, Bianca, de Boer-Veger, Nienke J., Buunk, Anne-Marie, Houwink, Elisa J. F., Risselada, Arne, Rongen, Gerard A. P. J. M., van Schaik, Ron H. N., Swen, Jesse J., Touw, Daan J., van Westrhenen, Roos, Deneer, Vera H. M., and Guchelaar, Henk-Jan

Abstract

By developing evidence-based pharmacogenetics guidelines to optimize pharmacotherapy, the Dutch Pharmacogenetics Working Group (DPWG) aims to advance the implementation of pharmacogenetics (PGx). This guideline outlines the gene-drug interaction of CYP2C9and HLA-Bwith phenytoin, HLA-Aand HLA-Bwith carbamazepine and HLA-Bwith oxcarbazepine and lamotrigine. A systematic review was performed and pharmacotherapeutic recommendations were developed. For CYP2C9intermediate and poor metabolisers, the DPWG recommends lowering the daily dose of phenytoin and adjust based on effect and serum concentration after 7–10 days. For HLA-B*15:02carriers, the risk of severe cutaneous adverse events associated with phenytoin, carbamazepine, oxcarbazepine, and lamotrigine is strongly increased. For carbamazepine, this risk is also increased in HLA-B*15:11and HLA-A*31:01carriers. For HLA-B*15:02, HLA-B*15:11and HLA-A*31:01positive patients, the DPWG recommends choosing an alternative anti-epileptic drug. If not possible, it is recommended to advise the patient to report any rash while using carbamazepine, lamotrigine, oxcarbazepine or phenytoin immediately. Carbamazepine should not be used in an HLA-B*15:02positive patient. DPWG considers CYP2C9genotyping before the start of phenytoin “essential” for toxicity prevention. For patients with an ancestry in which the abovementioned HLA-alleles are prevalent, the DPWG considers HLA-B*15:02genotyping before the start of carbamazepine, phenytoin, oxcarbazepine, and lamotrigine “beneficial”, as well as genotyping for HLA-B*15:11and HLA-A*31:01before initiating carbamazepine.

Published
2024
Full Text
View/download PDF

50. Lessons learned from site-specific sampling and biological half-life of IGFII and IIE(68-88) peptide: a case study.

Author

Muller Kobold, Anneke C., de Haan, Jacco J., Bokkers, Reinoud P.H., Ruiter, Simeon J.S., van den Heuvel, Marius C., Lentjes, Eef G.W.M., Touw, Daan J., and de Jong, Koert P.

Subjects
PEPTIDES, HEPATIC veins, RENAL veins, INSULIN-like growth factor-binding proteins, SOMATOMEDIN A
Abstract

This article presents a case study on non-islet cell tumor induced hypoglycemia (NICTH), a rare condition associated with mesenchymal tumors. The study focuses on a patient with metastatic solitary fibrous tumors (SFT) and severe hypoglycemic symptoms. The researchers measured levels of insulin-like growth factor (IGF)-II and IIE(68-88) peptide in various sampling sites, including the hepatic vein draining the largest SFT metastasis. They also measured these substances in peripheral venous blood samples taken at different timepoints after tumor resection to determine their half-life and correlate the levels with tumor size and clinical parameters. The findings provide insight into the contribution of liver metastases to hormone production and highlight the importance of site-specific sampling in understanding the metabolism of tumor cells. However, the study suggests that site-specific sampling may have limited value in identifying the dominant hormone-producing site in patients with SFT. [Extracted from the article]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results